Jupiter Neurosciences Inc (JUNS)

[US Market News]

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

April 13, 2026 8:00 PM
Newsfile

Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, will present at the Centri Capital Conference on Tuesday, April 14 at Nasdaq in New York City.

Christer Rosén, Chairman and CEO will discuss the Company's recent performance and future growth plans.

The Centri Capital Conference will gather attendees from across the capital markets ecosystem and investment community, including investment bankers, private equity investors, family offices, and high-net-worth individuals. The highly anticipated conference will feature company presentations and fireside chats, facilitated investor 1:1 meetings, and panel discussions featuring insights from thought leaders in the capital markets space.

Jupiter Neurosciences, Inc. joins a distinguished list of exciting and disruptive presenting companies like Grayscale, Orchestra BioMed, CoinShares, ReserveOne, MVB Financial and many others. Also included in the event at Nasdaq are key sponsors in the capital markets space, including Morgan Stanley, DFIN, Chardan, Gusto, CBIZ, ICR and The Money Channel.

"The companies involved with the Centri Capital Conference embody the innovation and diversity shaping today’s capital markets,” says Michael Aiello, CEO & Managing Partner of Centri. “We are excited to welcome them to Nasdaq for investor 1:1 meetings and meaningful exchanges with leaders from across the industry."

Companies and investors interested in presenting, attending, or sponsoring the Centri Capital Conference can learn more here: www.CentriConsulting.com/capital-conference.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated improved bioavailability in clinical studies. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

About Centri Business Consulting, LLC

Centri Business Consulting provides the highest quality advisory consulting services to its clients by being reliable and responsive to their needs. Centri provides companies with the expertise they need to meet their reporting demands. Centri specializes in financial reporting, internal controls, technical accounting research, valuation, mergers & acquisitions, and tax, CFO and HR advisory services for companies of various sizes and industries. From complex technical accounting transactions to monthly financial reporting, our professionals can offer any organization the specialized expertise and multilayered skillsets to ensure the project is completed timely and accurately.

For additional Information, please contact:

Jupiter Neurosciences, Inc.
Christer Rosén
[phone]
[e-mail]
https://jupiterneurosciences.com/

Original: Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14